Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Rheumatoid Arthritis
Both
Rheumatoid Arthritis
Trial Information
Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia
Inclusion Criteria:
- Rheumatoid arthritis
- Receipt of abatacept, other biologic disease-modifying drug, or any non- biologic
disease-modifying anti-rheumatic drug
- Age 18 years or older
Exclusion Criteria:
- Below 18 years of age
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Serious infection
Outcome Time Frame:
Every 2 years throughout the study
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
European Union: European Medicines Agency
Study ID:
IM101-213
NCT ID:
NCT01247766
Start Date:
December 2010
Completion Date:
August 2018
Related Keywords:
- Rheumatoid Arthritis
- Arthritis
- Arthritis, Rheumatoid
Name | Location |
|---|
